Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key genetic biomarkers and therapeutic potential in multiple sclerosis: Insights from integrated bioinformatics and mendelian randomization

11 Aug 2026

Abstract excerpt

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. This study aimed to identify key genetic and immune-related biomarkers involved in MS pathogenesis and to explore structurally plausible therapeutic targets. MATERIALS AND METHODS: Publicly available gene-expression datasets were...

Topics

Join the communities discussing this publication.

Genetic Associations and Epidemiology
Genomics and Rare Diseases
Multiple Sclerosis Research Studies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 42585774
DOI: 10.1016/j.compbiolchem.2026.109324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key genetic biomarkers and therapeutic potential in multiple sclerosis: Insights from integrated bioinformatics and mendelian randomizationPMID 42585774Read ↗

Prioritization of risk genes in multiple sclerosis by a refined Bayesian framework followed by tissue-specificity and cell type feature assessment.Semantic proximity Read ↗

Integrated multi-omics and machine learning prioritize key immune genes for multiple sclerosis risk prediction.Semantic proximity Read ↗

Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis.Semantic proximity Read ↗

Breakdown of multiple sclerosis genetics to identify an integrated disease network and potential variant mechanismsSemantic proximity Read ↗

Integrated analyses of single-cell transcriptome and Mendelian randomization reveal the protective role of FCRL3 in multiple sclerosis.Semantic proximity Read ↗

Epigenetic and genetic insights for tailored therapeutic strategies in multiple sclerosis.Semantic proximity Read ↗

The genetic architecture of multiple sclerosis in 2026: From susceptibility to disease progression.Semantic proximity Read ↗

Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosisSemantic proximity Read ↗

Single-Cell and Mendelian Randomization Analyses Identify Key Genes Common to COVID-19 and Multiple Sclerosis.Semantic proximity Read ↗

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.Semantic proximity Read ↗

Proteome-Wide Mendelian Randomization Identifies Causal Proteins for Multiple Sclerosis Susceptibility and Severity.Semantic proximity Read ↗

Bioinformatics analysis of the potential biomarkers of Multiple Sclerosis and Guillain-Barré syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.